Patents by Inventor SHAOXIN FENG

SHAOXIN FENG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220267341
    Abstract: Solid state forms of tert-buty 1 (S)-2-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-1-oxo-2,5-diazaspiro[3.4] octane-5-carboxylate, pharmaceutical compositions, preparation, and uses thereof.
    Type: Application
    Filed: June 23, 2020
    Publication date: August 25, 2022
    Inventors: Xiaoda YUAN, Shaoxin FENG, Danny T. DING, William R. PERRAULT
  • Patent number: 10065984
    Abstract: Provided herein are multiple solid forms of a defined steroid-like compound, and methods for the preparation and use thereof. In one aspect, there is provided a crystalline form of said steroid-like compound, and methods for the preparation and use thereof. In another aspect, there is provided a substantially amorphous form of said steroid-like compound, and methods for the preparation and use thereof. In yet another aspect, there are provided compositions containing compounds according to the present invention. In certain aspects, such compositions are suitable for delivery of active agents according to the present invention to a subject in need thereof. In another aspect of the invention, there are provided methods for the treatment of a variety of indications, including glaucoma, ocular hypertension, and the like. In still another aspect of the present invention, there are provided kits containing compounds according to the present invention and/or compositions containing same.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: September 4, 2018
    Assignee: ALLERGAN, INC.
    Inventors: Shaoxin Feng, Scott W. Smith, Olivier M. G. Lambert, Suzanne M. Buttar
  • Patent number: 9855232
    Abstract: The invention provides new crystalline forms of 7-[3,5-Dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-hept-5-enoic acid. This compound is commonly referred to as “bimatoprost acid.” The novel crystalline forms are designated forms I, II, and III. The invention crystalline forms are useful for solid ocular implant formulations, utilized in the treatment of various ocular conditions, such as, for example, ocular hypertension. In addition, invention crystalline forms are useful for solid or semisolid dosage formulations used to treat ocular hypertension.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: January 2, 2018
    Assignee: ALLERGAN, INC.
    Inventors: Ke Wu, Shaoxin Feng, Thomas K. Karami, Scott W. Smith
  • Publication number: 20160175269
    Abstract: The invention provides new crystalline forms of 7-[3,5-Dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-hept-5-enoic acid. This compound is commonly referred to as “bimatoprost acid.” The novel crystalline forms are designated forms I, II, and III. The invention crystalline forms are useful for solid ocular implant formulations, utilized in the treatment of various ocular conditions, such as, for example, ocular hypertension. In addition, invention crystalline forms are useful for solid or semisolid dosage formulations used to treat ocular hypertension.
    Type: Application
    Filed: July 17, 2015
    Publication date: June 23, 2016
    Inventors: Ke Wu, Shaoxin Feng, Thomas K. Karami, Scott W. Smith
  • Patent number: 9120738
    Abstract: The invention provides new crystalline forms of 7-[3,5-Dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-hept-5-enoic acid. This compound is commonly referred to as “bimatoprost acid.” The novel crystalline forms are designated forms I, II, and III. The invention crystalline forms are useful for solid ocular implant formulations, utilized in the treatment of various ocular conditions, such as, for example, ocular hypertension. In addition, invention crystalline forms are useful for solid or semisolid dosage formulations used to treat ocular hypertension.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: September 1, 2015
    Assignee: Allergan, Inc.
    Inventors: Ke Wu, Shaoxin Feng, Thomas K. Karami, Scott W. Smith
  • Publication number: 20150209342
    Abstract: The present invention provides topical dermal compositions including the compositions of the invention are useful for treating a variety of conditions associated with excess sebum production, such as, for example, acne.
    Type: Application
    Filed: January 28, 2015
    Publication date: July 30, 2015
    Inventors: Guang Wei Lu, Fangjing Wang, Shaoxin Feng, Hui Liu, Patrick Hughes, Scott Smith, Rong Yang
  • Publication number: 20150166597
    Abstract: Provided herein are multiple solid forms of a defined steroid-like compound, and methods for the preparation and use thereof. In one aspect, there is provided a crystalline form of said steroid-like compound, and methods for the preparation and use thereof. In another aspect, there is provided a substantially amorphous form of said steroid-like compound, and methods for the preparation and use thereof. In yet another aspect, there are provided compositions containing compounds according to the present invention. In certain aspects, such compositions are suitable for delivery of active agents according to the present invention to a subject in need thereof. In another aspect of the invention, there are provided methods for the treatment of a variety of indications, including glaucoma, ocular hypertension, and the like. In still another aspect of the present invention, there are provided kits containing compounds according to the present invention and/or compositions containing same.
    Type: Application
    Filed: December 12, 2014
    Publication date: June 18, 2015
    Inventors: Shaoxin Feng, Scott W. Smith, Olivier M.G. Lambert, Suzanne M. Buttar
  • Publication number: 20140187636
    Abstract: The invention provides new crystalline forms of 7-[3,5-Dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-hept-5-enoic acid. This compound is commonly referred to as “bimatoprost acid.” The novel crystalline forms are designated forms I, II, and III. The invention crystalline forms are useful for solid ocular implant formulations, utilized in the treatment of various ocular conditions, such as, for example, ocular hypertension. In addition, invention crystalline forms are useful for solid or semisolid dosage formulations used to treat ocular hypertension.
    Type: Application
    Filed: December 20, 2013
    Publication date: July 3, 2014
    Applicant: ALLERGAN, INC.
    Inventors: KE WU, SHAOXIN FENG, THOMAS K. KARAMI, SCOTT W. SMITH